Literature DB >> 34800609

Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes: Results from the ADVANCE Trial.

Mary R Rooney1, Dan Wang2, J William McEvoy3, Stephen P Juraschek4, John Chalmers5, Mark Woodward6, Elizabeth Selvin2.   

Abstract

We found that 1,5-anhydroglucitol-a marker of glucose excursions-was not independently associated with subclinical cardiac damage, nor with vascular outcomes, in the ADVANCE Trial. High-sensitivity cardiac troponin T and N-terminal pro-b-type natriuretic peptide provided better prognostic information regarding vascular risk in diabetes than 1,5-anhydroglucitol.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Year:  2021        PMID： 34800609      PMCID： PMC8688324          DOI： 10.1016/j.diabres.2021.109148

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  19 in total

1.  Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system.

Authors:  B Cauliez; J Guignery; S Marinier; I Mariau; A Lavoinne
Journal:  Ann Clin Biochem       Date:  2008-05       Impact factor: 2.057

Review 2.  Glycaemic variability in diabetes: clinical and therapeutic implications.

Authors:  Antonio Ceriello; Louis Monnier; David Owens
Journal:  Lancet Diabetes Endocrinol       Date:  2018-08-13       Impact factor: 32.069

3.  Association of a Biomarker of Glucose Peaks, 1,5-Anhydroglucitol, With Subclinical Cardiovascular Disease.

Authors:  Menglu Liang; John William McEvoy; Yuan Chen; A Richey Sharrett; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2016-08-01       Impact factor: 19.112

Review 4.  Cardiovascular disease and 1,5-anhydro-d-glucitol.

Authors:  Nobutaka Ikeda; Yukio Hiroi
Journal:  Glob Health Med       Date:  2019-12-31

5.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

Authors:  Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

6.  Impact of serum 1,5-anhydro-d-glucitol level on prediction of major adverse cardiac and cerebrovascular events in non-diabetic patients without coronary artery disease.

Authors:  Nobutaka Ikeda; Hisao Hara; Yukio Hiroi; Masato Nakamura
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

7.  Serum 1,5-Anhydroglucitol: Risk Factor of Acute Ischemic Stroke and Transient Ischemic Attack in Well-Controlled Diabetes.

Authors:  Yuji Shiga; Masaru Kuriyama; Yuhei Kanaya; Shinichi Takeshima; Makoto Takemaru; Kazuhiro Takamatsu; Yutaka Shimoe; Yasunori Fujikawa; Masakazu Nishigaki
Journal:  Cerebrovasc Dis       Date:  2017-10-26       Impact factor: 2.762

8.  Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.

Authors:  Elizabeth Selvin; Andreea Rawlings; Pamela Lutsey; Nisa Maruthur; James S Pankow; Michael Steffes; Josef Coresh
Journal:  Diabetes       Date:  2015-09-22       Impact factor: 9.461

Review 9.  Glycemic variability and cardiovascular disease in patients with type 2 diabetes.

Authors:  Marcela Martinez; Jimena Santamarina; Adrian Pavesi; Carla Musso; Guillermo E Umpierrez
Journal:  BMJ Open Diabetes Res Care       Date:  2021-03

10.  High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes.

Authors:  Olive Tang; Kunihiro Matsushita; Josef Coresh; Chiadi Ndumele; John W McEvoy; A Richey Sharrett; Ron Hoogeveen; Christie M Ballantyne; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2020-08-11       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.